Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Avadel AVDL -- Ignore unavailable to you. Want to Upgrade?

To: sammaster who wrote (177)	9/4/2007 3:50:33 PM
From: IRWIN JAMES FRANKEL	Respond to of 240

>>you would assume in a month if there were 20k new scripts written that total scripts would jump from 40k to 60k next month? No. Don't think so. Keep in mind new scripts are not all new in the sense of a patient starting for the first time on the drug. Eg. If a script is written for a single fill - then it will be an NRX and so will be the next script. In fact each time a new script is written - even if for the same drug/dose/patient, the first fill is an NRX. With patients who may be titrating up the dosages there will be an even greater number of relative NRX's. My read - and others who understand this better can correct me, is that the scripts are ramping slowly. And we have not yet seen the effect that gCoreg will have. ij